The 3 most commonly recorded adverse events were rash ( 54.1 % ) , fatigue ( 19.7 % ) , and diarrhea ( 16.4 % ) in the erlotinib group and fatigue ( 25.8 % ) , nausea ( 24.2 % ) , and anorexia ( 14.5 % ) in the pemetrexed group .